3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Classical hematology
2
Gastrointestinal
1
Conditions
Venous Thrombosis
2
Venous Thromboembolism
2
Pulmonary Embolism
2
Gastrointestinal Neoplasms
1
Interventions
Epoetin Alfa
27
Darbepoetin alfa
13
Cytarabine
9
Dalteparin
8
Rivaroxaban
7
Daunorubicin
7
apixaban
6
Etoposide
6
Methotrexate
5
Idarubicin
5
Heparin, Low-Molecular-Weight
5
Cyclophosphamide
5
emicizumab
4
Tinzaparin
4
Thioguanine
4
Mitoxantrone
4
Granulocyte Colony-Stimulating Factor
4
Filgrastim
4
Enoxaparin
4
pegfilgrastim
3
hetrombopag
3
epoetin beta
3
Saline Solution
3
Radiotherapy
3
Hydrocortisone
3
Erythropoietin
3
Dexamethasone
3
Aspirin
3
Asparaginase
3
telapristone acetate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
abelacimab
×
Classical hematology
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled
NCT05171049
2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3
Terminated
1,150 enrolled